Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.606,93
0,18%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lipella Pharmaceuticals Inc (LIPO) Lipella Pharmaceuticals Inc (LIPO) Notizie

LIPO

Lipella Pharmaceuticals (LIPO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LIPO
DataOraFonteTitoloSimboloCompagnia
31/05/202414:00GlobeNewswire Inc.Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen PlanusNASDAQ:LIPOLipella Pharmaceuticals Inc
29/05/202414:00GlobeNewswire Inc.Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:LIPOLipella Pharmaceuticals Inc
21/05/202414:00GlobeNewswire Inc.Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2bNASDAQ:LIPOLipella Pharmaceuticals Inc
15/05/202422:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIPOLipella Pharmaceuticals Inc
09/05/202422:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIPOLipella Pharmaceuticals Inc
06/05/202422:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
17/04/202414:00GlobeNewswire Inc.Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseNASDAQ:LIPOLipella Pharmaceuticals Inc
05/04/202414:00GlobeNewswire Inc.Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024NASDAQ:LIPOLipella Pharmaceuticals Inc
03/04/202414:00GlobeNewswire Inc.Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic CystitisNASDAQ:LIPOLipella Pharmaceuticals Inc
07/03/202421:23GlobeNewswire Inc.PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare DiseaseNASDAQ:LIPOLipella Pharmaceuticals Inc
05/03/202414:00GlobeNewswire Inc.Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical PipelineNASDAQ:LIPOLipella Pharmaceuticals Inc
27/02/202423:04Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
27/02/202422:51Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LIPOLipella Pharmaceuticals Inc
20/02/202414:00GlobeNewswire Inc.Lipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceNASDAQ:LIPOLipella Pharmaceuticals Inc
09/02/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIPOLipella Pharmaceuticals Inc
07/02/202423:29Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
01/02/202422:09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIPOLipella Pharmaceuticals Inc
03/01/202422:59Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LIPOLipella Pharmaceuticals Inc
20/12/202314:00GlobeNewswire Inc.Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones AccomplishedNASDAQ:LIPOLipella Pharmaceuticals Inc
28/11/202323:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIPOLipella Pharmaceuticals Inc
10/11/202314:00PR Newswire (US)FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host DiseaseNASDAQ:LIPOLipella Pharmaceuticals Inc
07/11/202323:22Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:LIPOLipella Pharmaceuticals Inc
01/11/202321:06Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:LIPOLipella Pharmaceuticals Inc
25/10/202322:05PR Newswire (US)Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:LIPOLipella Pharmaceuticals Inc
24/10/202314:00PR Newswire (US)Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:LIPOLipella Pharmaceuticals Inc
20/10/202314:00PR Newswire (US)Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen PlanusNASDAQ:LIPOLipella Pharmaceuticals Inc
10/10/202322:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:LIPOLipella Pharmaceuticals Inc
21/09/202314:30PR Newswire (US)Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and NephrologyNASDAQ:LIPOLipella Pharmaceuticals Inc
23/06/202322:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LIPOLipella Pharmaceuticals Inc
21/06/202323:08Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LIPOLipella Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LIPO

La tua Cronologia

CSE
BGRD
Braingrid
USOTC
NHBAF
Nichiban (PK)
NASDAQ
OTRK
Ontrak
LSE
TR27
4 1/4% 27
BIT
UB9FH1
Unicredit Bank
BIT
1JPM
JPMorgan Chase &
LSE
35XB
Paragon M. S47
LSE
0A8C
Airbnb
BIT
O8JQD7
Morgan Stanley BV
OKEX
CHATBTC
EU
U897S
U897S
BIT
P1IKF2
BNP Paribas Issuance
COIN
DVPUST
Decentralized Vulnerability Plat
EU
RNOBY
Renault SA 1% 18apr2024
EU
RHFAC
Region Hauts De France 0...
USOTC
CLPBY
Coloplast AS (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network